Skip to the latest updates
ClinteloClinical Intelligence for Physicians
Get Started
Drugs

Juvmo (tavapadon)

AbbVie · FDA approval

First selective D1/D5 dopamine agonist approved for Parkinson's disease.

Clinical summary

A once-daily oral tablet for adults with Parkinson's disease, with or without levodopa; unlike existing agonists, which act mainly on D2/D3 receptors, it selectively activates D1/D5. In TEMPO-3, as adjunct to levodopa in patients with motor fluctuations, daily 'on' time without troublesome dyskinesia rose by 1.7 hours versus 0.6 hours with placebo. Warnings include orthostatic hypotension, hallucinations, dyskinesia and impulse-control urges.

Read the primary source: AbbVie press release

More innovations

AI & Digital Health

neuropacs

Neuropacs · FDA De Novo

Machine-learning MRI aid helps tell MSA-P and PSP apart from Parkinson's.

Cloud software that analyzes standard 3T diffusion MRI, with no radiotracer, to help distinguish multiple system atrophy (parkinsonian variant) and progressive supranuclear palsy from Parkinson's disease. Authorization created a new device category and rested on a prospective, NIH-supported study at 21 Parkinson Study Group centers. It is an adjunct only: it does not exclude other causes of parkinsonism, and management should not rest on its output alone.

NeurologyView Innovation
Drugs

Icotyde (icotrokinra)

Johnson & Johnson · FDA approval

The first oral peptide that blocks the IL-23 receptor, approved for plaque psoriasis.

A once-daily oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis in adults and in children 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. In the head-to-head ICONIC-ADVANCE 1 and 2 trials against deucravacitinib, about 70% of patients reached IGA 0/1 and 55% reached PASI 90 at week 16. It is taken on an empty stomach, at least 30 minutes before eating.

DermatologyView Innovation
Medical Technology

Libre Duo

Abbott · FDA De Novo

First wearable sensor that tracks ketones and glucose together.

A 10-day sensor for people with diabetes aged 2 and older that measures ketones and glucose in interstitial fluid every minute and sends readings, trends and rising-level alerts to a smartphone. Across six clinical studies in more than 600 participants it tracked clinically meaningful ketone differences, including elevated ketones before the onset of diabetic ketoacidosis. Ketone readings should be interpreted with glucose values and symptoms, and do not replace confirmatory testing before treatment decisions.

EndocrinologyView Innovation